The principal business and principal office address for Rhino Cayman is 90 Fort Street, Suite 303, Grand Cayman, Cayman Islands. The principal business and principal office address for Mr. Pelham is 90 Fort Street, Suite 303, Grand Cayman, Cayman Islands.

Rhino Cayman's principal business is making investments. Mr. Pelham is the sole shareholder and a director of Rhino Cayman and Mr. Pelham is the Chairman and a shareholder of the Issuer.

During the past five years, neither (1) Rhino Cayman nor any of its officers or directors, nor (2) Mr. Pelham, have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).

During the past five years, neither (1) Rhino Cayman nor any of its officers or directors, nor (2) Mr. Pelham, have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Rhino Cayman is a Cayman Islands exempted company. Mr. Pelham is a British citizen.

No Reporting Person has purchased Ordinary Shares in the past sixty (60) days.

The Reporting Persons acquired and hold the securities of the Issuer for investment purposes. Other than as discussed herein, the Reporting Persons do not have any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation , involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any other person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act; or (j) any similar action to those enumerated above. The Reporting Persons may acquire additional securities of the Issuer, or retain, or sell all or a portion of the securities then held in open market or in privately negotiated transactions. Mr. Pelham is the Chairman of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to the matters described in this Item 4. On August 14, 2026, the Issuer entered into an Amended and Restated Sale and Purchase Agreement (the "A&R SPA") with the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries ("Resulticks"). The A&R SPA is attached hereto as Exhibit 99.1. Pursuant to the A&R SPA, the Issuer agreed to acquire all of the issued and outstanding share capital of Resulticks, held by the Sellers, in exchange for US$1.05 billion, payable entirely in equity through the issuance of 600,000,000 newly issued Ordinary Shares to the Sellers pro rata to their respective ownership of Resulticks based upon the agreed to share price of US$1.75 per share. It is expected that the Transaction will close on or before October 30, 2026. However, the closing of the Transaction is subject to various conditions and there can be no assurance that the Transaction will close. In connection with the Transaction, and pursuant to the A&R SPA and the Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Mr. Pelham, Rhino Cayman, Radhika Sundaram and Rambacthavachalam Dhakshina Moorthy (the "Deed of Undertaking"), the parties have agreed that Mr. Pelham and Rhino Cayman shall terminate and cancel the 51% Warrant, the Outstanding IPO Warrants, as defined below, and all restricted stock units ("RSUs") and performance stock units ("PSUs"), including the 1,771 RSUs and 1,771 PSUs issued to Mr. Pelham pursuant to the Issuer's Incentive Plan. The Deed of Undertaking is attached hereto as Exhibit 99.2. The "51% Warrant" is the 4,170,520 warrants to purchase 51% of the outstanding Ordinary Shares at time of exercise at a price of $6.13 per warrant, which was granted by the Issuer to Rhino Cayman on July 15, 2024 and expires on May 27, 2029. The "Outstanding IPO Warrants" are the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029. In exchange for Rhino Cayman's termination and cancellation of the 51% Warrant, Outstanding IPO Warrants, RSUs and PSUs, pursuant to the A&R SPA and the Deed of Undertaking, Rhino Cayman will be allotted and issued 40 million Ordinary Shares at the closing of the Transaction (the "Rhino Shares"). The Rhino Shares are subject to forfeiture in accordance with the terms of the A&R SPA and the Deed of Undertaking.

Rhino Cayman beneficially owns (i) 731,707 Ordinary Shares and (ii) 32,316,366 Ordinary Shares underlying warrants, which are exercisable within the next sixty (60) days, which amounts to 33,048,073 Ordinary Shares or 40.1% of the total outstanding Ordinary Shares. Rhino Cayman owns the following warrants. (i) Rhino Cayman the 51% Warrant, which if fully exercised, will result in the issuance of shares equal to 51% of the Issuer's outstanding Ordinary Shares at the time the warrants are exercised and such amount will be prorated in the event of partial exercise of the warrants (for the purpose of this Schedule 13D we have assumed these warrants are exercisable for 26,566,366 Ordinary Shares which is 51% of the 50,130,130 Ordinary Shares the Issuer had issued outstanding as of August 10, 2026), and (ii) the Outstanding IPO Warrants which consist of the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029.. Mr. Pelham beneficially owns (i) 303,400 Ordinary Shares in his own name and (ii) 33,048,073 Ordinary Shares beneficially held by Rhino Cayman, which amounts to 33,351,473 Ordinary Shares or 40.5% of the total outstanding Ordinary Shares. Mr. Pelham individually and through his position as director of Rhino Cayman, may be deemed to hold the power to vote or direct the vote and dispose of or direct the disposition of the Ordinary Shares beneficially held by the Reporting Persons.

Rhino Cayman beneficially owns (i) 731,707 Ordinary Shares and (ii) 32,316,366 Ordinary Shares underlying warrants, which are exercisable within the next sixty (60) days, which amounts to 33,048,073 Ordinary Shares or 40.1% of the total outstanding Ordinary Shares. Rhino Cayman owns the following warrants. (i) Rhino Cayman the 51% Warrant, which if fully exercised, will result in the issuance of shares equal to 51% of the Issuer's outstanding Ordinary Shares at the time the warrants are exercised and such amount will be prorated in the event of partial exercise of the warrants (for the purpose of this Schedule 13D we have assumed these warrants are exercisable for 26,566,366 Ordinary Shares which is 51% of the 50,130,130 Ordinary Shares the Issuer had issued outstanding as of August 10, 2026), and (ii) the Outstanding IPO Warrants which consist of the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029.. Mr. Pelham beneficially owns (i) 303,400 Ordinary Shares in his own name and (ii) 33,048,073 Ordinary Shares beneficially held by Rhino Cayman, which amounts to 33,351,473 Ordinary Shares or 40.5% of the total outstanding Ordinary Shares. Mr. Pelham individually and through his position as director of Rhino Cayman, may be deemed to hold the power to vote or direct the vote and dispose of or direct the disposition of the Ordinary Shares beneficially held by the Reporting Persons.

On August 17, 2026, Mr. Pelham sold 294,380 Ordinary Shares in a private transaction for $294,380 or $1.00 per share. On August 17, 2026, Rhino Cayman sold 6,908,540 Ordinary Shares in three separate private transactions for aggregate consideration of $6,908,540 or $1.00 per share.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares owned by the Reporting Persons.

Not applicable.

On November 7, 2025, the Issuer granted Mr. Pelham Restrictive Share Units ("RSUs") to acquire 1,771 Ordinary Shares. The RSUs vest 1/3 on March 31, 2026, 1/3 on March 31, 2027, and 1/3 on March 31, 2028, provided certain conditions are satisfied. On November 7, 2025, the Issuer issued Mr. Pelham Performance Share Units ("PSUs") to acquire 1,771 Ordinary Shares. The PSUs all vest on March 31, 2028, provided certain conditions are satisfied. On August 14, 2026, the Issuer entered into an Amended and Restated Sale and Purchase Agreement (the "A&R SPA") with the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries ("Resulticks"). The A&R SPA is attached hereto as Exhibit 99.1. Pursuant to the A&R SPA, the Issuer agreed to acquire all of the issued and outstanding share capital of Resulticks, held by the Sellers, in exchange for US$1.05 billion, payable entirely in equity through the issuance of 600,000,000 newly issued Ordinary Shares to the Sellers pro rata to their respective ownership of Resulticks based upon the agreed to share price of US$1.75 per share. It is expected that the Transaction will close on or before October 30, 2026. However, the closing of the Transaction is subject to various conditions and there can be no assurance that the Transaction will close. In connection with the Transaction, and pursuant to the A&R SPA and the Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Mr. Pelham, Rhino Cayman, Radhika Sundaram and Rambacthavachalam Dhakshina Moorthy (the "Deed of Undertaking"), the parties have agreed that Mr. Pelham and Rhino Cayman shall terminate and cancel the 51% Warrant, as defined below, the Outstanding IPO Warrants, as defined below, and all restricted stock units ("RSUs") and performance stock units ("PSUs"), including the 1,771 RSUs and 1,771 PSUs issued to Mr. Pelham pursuant to the Issuer's Incentive Plan. The Deed of Undertaking is attached hereto as Exhibit 99.2. The "51% Warrant" is the 4,170,520 warrants to purchase 51% of the outstanding Ordinary Shares at time of exercise at a price of $6.13 per warrant, which was granted by the Issuer to Rhino Cayman on July 15, 2024 and expires on May 27, 2029. The "Outstanding IPO Warrants" are the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029. In exchange for Rhino Cayman's termination and cancellation of the 51% Warrant, Outstandng IPO Warrants, RSUs and PSUs, pursuant to the A&R SPA and the Deed of Undertaking, Rhino Cayman will be allotted and issued 40 million Ordinary Shares at the closing of the Transaction (the "Rhino Shares"). The Rhino Shares are subject to forfeiture in accordance with the terms of the A&R SPA and the Deed of Undertaking. Mr. Pelham is a director and the sole equityholder of Rhino Cayman, which is an investment holding company and Mr. Pelham is the Chairman and a shareholder of Diginex Limited. A Joint Filing Agreement is attached hereto as Exhibit 99.1.

Exhibit No. Description 99.1. Amended and Restated Sale and Purchase Agreement, dated August 14, 2026, by and between Diginex Limited and the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries, is attached as Exhibit 10.1 to the Issuer's Form 6-K filed with the Commission on August 17, 2026, and is incorporated herein by reference. 99.2 Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Miles Christian Pelham, Rhino Ventures Limited, Radhika Sundaram and Rambacthavachalam Dhakshina Moorthy, is attached as Exhibit 10.2 to the Issuer's Form 6-K filed with the Commission on August 17, 2026, and is incorporated herein by reference. 99.3 Joint Filing Agreement by and among the Reporting Persons.